Specify a stock or a cryptocurrency in the search bar to get a summary
Lisata Therapeutics Inc.
LSTALisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Address: 110 Allen Road, Basking Ridge, NJ, United States, 07920
Analytics
WallStreet Target Price
14 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LSTA
Dividend Analytics LSTA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LSTA
Stock Valuation LSTA
Financials LSTA
Results | 2019 | Dynamics |